Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

NCT03168256 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.

NCT NCT03168256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03168256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Can-Fite BioPharma
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2018
Completion date
April 27, 2022
Enrollment
528 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis